双靶向治疗骨代谢病的理想候选药奥金肽  

Osgentide:a rational drug candidate for dual-targeting treatment of bone-metabolic diseases

作　　者：王德心[1] 韩香[1] 林浩[1] 杨潇骁[1] 冯鹤鹤[1] 

机构地区：[1]中国医学科学院北京协和医学院药物研究所,北京100050

出　　处：《中国新药杂志》2009年第1期3-6,11,共5页Chinese Journal of New Drugs

基　　金：国家自然科学基金(30672529)

摘　　要：许多骨代谢病,如骨质疏松(OP)的病理过程是受破骨细胞(OC)过度活跃及成骨细胞(OB)增殖下降两个环节共同调控的。目前临床上治疗OP的主流药物(除PTH片段肽外)均为以OC为靶点的骨吸收抑制剂。文中概述了成骨生长肽(OGP)的功能、结构改造先导物奥金肽对实验性大鼠骨质疏松的治疗作用;比较了奥金肽与PTH片段肽在化学特征、药理活性、不良反应及制备成本等方面的特点。对骨吸收抑制剂与骨形成促进剂联合应用的前景进行了讨论。Many bone metabolism-related diseases are usually modulated by both osteoclasts（OC） and osteoblasts（OB）. However, the drugs currently used in clinic for osteoporosis, except PTH peptide, are bone absorption inhibitors（OC targeting drugs）. As concerns bone-formation stimulator, the activity of osteogenic growth peptide （OGP） , the effect of osgentide on experimental osteoporosis （OP）, structurally modified leading compounds from OGP were described. The chemical character, pharmacological behavior, side-effect and productive cost between osgentide and PTH peptides were compared. Moreover, the combined treatment for bone metabolic diseases with bone-absorption inhibitor and bone-formation stimulator were also discussed.

关 键 词：奥金肽 成骨生长肽 成骨细胞增殖 骨质疏松 双靶向联合用药 

分 类 号：R68[医药卫生—骨科学]